ReviewCurrent Alzheimer research2010
Why so few drugs for Alzheimer's disease? Are methods failing drugs?
Review in Current Alzheimer research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer's Disease: Results from a Double-Blind, Placebo-Controlled Trial.Current Alzheimer research · 2017Trial
- Phenserine efficacy in Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2010Trial
- NaI/PPhBeilstein journal of organic chemistry · 2023Article
- HGF Mediates Clinical-Grade Human Umbilical Cord-Derived Mesenchymal Stem Cells Improved Functional Recovery in a Senescence-Accelerated Mouse Model of Alzheimer's Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- Does traumatic brain injury hold the key to the Alzheimer's disease puzzle?Alzheimer's & dementia : the journal of the Alzheimer's Association · 2018Review
- Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015.Expert opinion on investigational drugs · 2017Article
- Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network.The journal of prevention of Alzheimer's disease · 2016Article
- Interactions of cyclodextrins and their derivatives with toxic organophosphorus compounds.Beilstein journal of organic chemistry · 2016Review
- The need for thorough phase II studies in medicines development for Alzheimer's disease.Alzheimer's research & therapy · 2015Article
- What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?The lancet. Psychiatry · 2015Review
- Lessons from a BACE1 inhibitor trial: off-site but not off base.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2014Article
- Linking Alzheimer's disease and type 2 diabetes mellitus via aberrant insulin signaling and inflammation.CNS & neurological disorders drug targets · 2014Review
- A new regulatory road-map for Alzheimer's disease drug development.Current Alzheimer research · 2014Review
- Advances in understanding Alzheimer's disease, and the contributions of current Alzheimer research: ten years on and beyond.Current Alzheimer research · 2014Article
- Alzheimer disease therapy--moving from amyloid-β to tau.Nature reviews. Neurology · 2013Review
- J-147 a Novel Hydrazide Lead Compound to Treat Neurodegeneration: CeeToxJournal of neurology & neurophysiology · 2013Article
- Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α-Synuclein synthesis, interleukin-1β release, and cholinergic action.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2013Article
- Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances?Alzheimer's & dementia : the journal of the Alzheimer's Association · 2013Article
- Was phenserine a failure or were investigators mislead by methods?Current Alzheimer research · 2012Article
- Advances in microRNA experimental approaches to study physiological regulation of gene products implicated in CNS disorders.Experimental neurology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Recent studies of Alzheimer's disease (AD) and other neuropsychiatric drug developments raise questions whether failures of some drugs occur due to flaws in methods. In three case studies of recent AD drug development failures with phenserine, metrifonate, and tarenflurbil we identified methodological lapses able to account for the failures. Errors in complex systems such as drug developments are both almost inescapable due to human mistakes and most frequently hidden at the time of occurrence and thereafter. We propose preemptive error management as a preventive strategy to exclude or control error intrusions into neuropsychiatric drug developments. We illustrate the functions we anticipate for a preemptive error management preventive strategy with a checklist and identify the limitations of this aspect of the proposal with three drug examples. This strategy applies core scientific practices to insure the quality of data within the current context of AD drug development practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.